Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome

Giuseppe Morgante; Valentina Cappelli; Libera Troìa; Vincenzo De Leo

doi:10.1080/13625187.2020.1736546

Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome

Giuseppe Morgante, Valentina Cappelli, Libera Troìa, Vincenzo De Leo

In: The European Journal of Contraception & Reproductive Health Care · 2020 · vol. 25(3) , pp. 176–181 · doi:10.1080/13625187.2020.1736546 · PMID:32191532 · W3012491756

article OA: closed CC0

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

Dienogest and drospirenone significantly increased SHBG, dehydroepiandrosterone sulfate, and total testosterone levels in PCOS patients, with dienogest having a stronger effect than cyproterone acetate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Our study showed that DNG exerted an important stimulatory effect on SHBG concentrations, which was less than that of DRSP but greater than that of CMA. Similar results were also obtained for dehydroepiandrosterone sulphate and total testosterone.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone via openalex
Comparative Pharmacology of Newer Progestogens via openalex
Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism via openalex
Effects of Combined Oral Contraceptive Ethinylestradiol (30 μg) and Dienogest (2 mg) on Carbohydrate Metabolism During 1 Year of Conventional or Extended-Cycle Use via openalex
<p>Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain</p> via openalex
Progestogens with Antiandrogenic Properties via openalex
The efficacy and tolerability of Valette®: a postmarketing surveillance study via openalex
The pharmacological profile of dienogest via openalex
doi:10.1097/aog.0b013e3182699a2b via openalex
doi:10.2741/e41 via openalex
doi:10.3109/09513590.2014.964201 via openalex
doi:10.1093/humrep/16.1.36 via openalex
doi:10.3109/09513590.2015.1006187 via openalex
doi:10.1016/j.fertnstert.2006.11.137 via openalex
doi:10.1016/j.contraception.2008.11.002 via openalex
doi:10.1016/s0002-9378(03)00950-5 via openalex
W2974971308 via openalex
doi:10.2174/1381612822666160720151243 via openalex
doi:10.2196/resprot.9024 via openalex
doi:10.1093/humrep/del407 via openalex
doi:10.1080/13625187.2016.1234598 via openalex
doi:10.1891/9780826123091.0025 via openalex
doi:10.1016/j.metabol.2017.05.001 via openalex
doi:10.2147/oajc.s85543 via openalex
doi:10.1093/humupd/dmw016 via openalex
doi:10.3109/09513590.2015.1014784 via openalex
doi:10.1016/j.maturitas.2012.01.018 via openalex
doi:10.1007/s12325-018-0810-1 via openalex
doi:10.1093/humrep/deh098 via openalex
doi:10.1186/s12958-016-0173-x via openalex
doi:10.1016/j.contraception.2008.10.017 via openalex
doi:10.1016/j.atherosclerosis.2007.03.002 via openalex
doi:10.1016/j.contraception.2010.04.002 via openalex

Source provenance

openalex: last seen: 2026-05-10T10:41:05.019363+00:00

License: CC0 · commercial use OK

[1] Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone via openalex

[2] Comparative Pharmacology of Newer Progestogens via openalex

[3] Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism via openalex

[4] Effects of Combined Oral Contraceptive Ethinylestradiol (30 μg) and Dienogest (2 mg) on Carbohydrate Metabolism During 1 Year of Conventional or Extended-Cycle Use via openalex

[5] <p>Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain</p> via openalex

[6] Progestogens with Antiandrogenic Properties via openalex

[7] The efficacy and tolerability of Valette®: a postmarketing surveillance study via openalex

[8] The pharmacological profile of dienogest via openalex

[9] doi:10.1097/aog.0b013e3182699a2b via openalex

[10] doi:10.2741/e41 via openalex

[11] doi:10.3109/09513590.2014.964201 via openalex

[12] doi:10.1093/humrep/16.1.36 via openalex

[13] doi:10.3109/09513590.2015.1006187 via openalex

[14] doi:10.1016/j.fertnstert.2006.11.137 via openalex

[15] doi:10.1016/j.contraception.2008.11.002 via openalex

[16] doi:10.1016/s0002-9378(03)00950-5 via openalex

[17] W2974971308 via openalex

[18] doi:10.2174/1381612822666160720151243 via openalex

[19] doi:10.2196/resprot.9024 via openalex

[20] doi:10.1093/humrep/del407 via openalex

[21] doi:10.1080/13625187.2016.1234598 via openalex

[22] doi:10.1891/9780826123091.0025 via openalex

[23] doi:10.1016/j.metabol.2017.05.001 via openalex

[24] doi:10.2147/oajc.s85543 via openalex

[25] doi:10.1093/humupd/dmw016 via openalex

[26] doi:10.3109/09513590.2015.1014784 via openalex

[27] doi:10.1016/j.maturitas.2012.01.018 via openalex

[28] doi:10.1007/s12325-018-0810-1 via openalex

[29] doi:10.1093/humrep/deh098 via openalex

[30] doi:10.1186/s12958-016-0173-x via openalex

[31] doi:10.1016/j.contraception.2008.10.017 via openalex

[32] doi:10.1016/j.atherosclerosis.2007.03.002 via openalex

[33] doi:10.1016/j.contraception.2010.04.002 via openalex